A flibercept (Eylea) is the most recent antivascular endothelial growth factor (anti-VEGF) product approved by the US Food and Drug Administration to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration. 1 Compared with the other anti-VEGF agents commonly used to treat CNV, bevacizumab (Avastin) and ranibizumab (Lucentis), aflibercept has a longer intravitreal half-life and a higher binding affinity to VEGF-A receptor. 2, 3 While this drug is capable of inhibiting both VEGF-A (all isoforms) and placental growth factor, it has not been shown to be superior to ranibizumab. However, aflibercept given every 4 weeks for 3 doses followed by administration every 8 weeks has been shown to have visual acuity outcomes equivalent to those from administration of ranibizumab every 4 weeks through 1
year, 1 providing an opportunity to evaluate its use in persistent retinal thickening from CNV despite years of monthly ranibizumab treatments. We provide an example of one such case demonstrating dramatic improvement 1 month after switching from 5 years of ranibizumab use to the first dose of aflibercept.
Report of a Case.
A 66-year-old African American man visited in February 2005 with symptoms of blurry vision in the right eye. Visual acuity measured 20/20 OD and 20/16 OS. Ophthalmoscopic examination showed multifocal serosanguineous pigment epithelial detachments in the subfoveal and extrafoveal regions of his right macula; the left fundus showed multiple large drusen without any sign of CNV. Fluorescein angiography revealed multifocal areas of occult CNV in the right eye, consistent with a polypoidal pattern of CNV (although no indocyanine green angiographic images were obtained). The area of extrafoveal CNV was treated with laser photocoagulation and the area of subfoveal CNV was observed, as no definite treatment was available for the subfoveal CNV at that time ( Figure 1A ). Sixteen months later (June 2006), visual acuity gradually decreased to 20/50 OD. Fluorescein angiography showed growth of the subfoveal CNV ( Figure 1B ). One dose of intravitreal bevaci- Figure 1F ). In July 2012, visual acuity remained 20/125 and OCT showed prominent intraretinal cystoid abnormalities with subfoveal fluid; the macular thickness had increased to 797 m despite continued monthly intravitreal ranibizumab injections (Figure 2A and B) . The patient then received 1 intravitreal injection of aflibercept (2 mg/ 0.05 mL). In August 2012 at the 4-week follow-up visit, visual acuity remained 20/125 and the patient noticed no change in his vision. Fluorescein angiography revealed decreased staining and leakage of the lesion ( Figure 2C ) and OCT showed dramatic resolution of intraretinal and subretinal fluid, with macular thickness decreasing from 797 to 320 m ( Figure 2D ). Only a few cystoid abnormalities overlying the fibrovascular tissue were seen, with marked attenuation of the outer retinal tissue apparent and prominent subfoveal scar. Outer retinal tubular formation, a round hyporeflective space with hyperreflective borders in the outer nuclear layer on B-scan OCT, suggestive of degenerating photoreceptors, 4 also was noted ( Figure 2D) . A second dose of intravitreal aflibercept was administered at this visit because of the improvement and to treat the residual thickening. Four weeks after the second injection, visual acuity remained 20/125 and OCT showed even smaller intraretinal cystoid abnormalities, with macular thickness decreasing to 258 m.
Comment.
Despite monthly administration of intravitreal anti-VEGF agents, a minority of patients still have sudden or gradual visual acuity loss with poor anatomical response to the monthly anti-VEGF treatments. The recent US Food and Drug Administration approval of aflibercept allows evaluation to determine whether this drug might cause a response in cases with persistent leak- 
Intralesional Ethanol for an Unresectable Epithelial Inclusion Cyst
E pithelial inclusion cysts are challenging to manage, particularly when large and extensive. Herein, we describe the use of intralesional ethanol to manage a cyst that was much too large to surgically excise.
Report of a Case.
A healthy 37-year-old woman was referred for decreasing vision in her left eye with no associated dis-comfort for 3 weeks. She had sustained a penetrating injury to the left eye with a pencil point at age 12 years. Her right eye was normal. Visual acuity was 20/160 OS and intraocular pressure was 14 mm Hg OS. On slitlamp examination, the inferior cornea was very thin and the iris was pulled down toward this region. The thin area was Seidel negative. The iris was bowed forward temporally from a cyst, resulting in a very shallow anterior chamber. The cyst almost completely filled the pupil. B-scan ultrasonography revealed a cyst behind the iris measuring 9.48ϫ4.00 mm.
The patient was prophylactically treated with an antibiotic eyedrop and instructed to return in a few days for a likely miniature penetrating keratoplasty. When she returned, the cyst had completely resolved. The inferior cornea had perforated and was Seidel positive.
Initially, after a successful miniature penetrating keratoplasty, her best-corrected visual acuity improved to 20/ 25, with no sign of recurrence. The excised corneal button had epithelium on the inner surface, confirming the diagnosis of an epithelial inclusion cyst. However, cyst recurrence was found at her 5-month follow-up visit (Figure 1) . On ultrasonography, the cyst measured 
